ArticleOncogene2018
DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor.
Abstract read
In one paragraph
Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 61 citations in OpenAlex.
- DHX15 as a novel immune-related prognostic biomarker in breast cancer: An integrated bioinformatics analysis withOncology letters · 2026Article
- SIAH2-EPHB6 axis enhances filopodia formation in hepatocellular carcinoma cells by regulating RHOF.Cell & bioscience · 2026Article
- DHX15 overexpression suppresses colorectal cancer cell line proliferation.Oncology letters · 2026Article
- Construction of a Prognostic Model Using RNA Processing Factor Genes and the Key Role of NSUN6 in Glioma Outcomes.Journal of cellular and molecular medicine · 2025Article
- DHX15 inhibits mouse APOBEC3 deamination.PLoS pathogens · 2025Article
- The role of ubiquitination and deubiquitination in urological tumours.Frontiers in pharmacology · 2025Review
- DHX15 and Rig-I Coordinate Apoptosis and Innate Immune Signaling by Antiviral RNase L.Viruses · 2024Article
- Competitive Microarray Screening Reveals Functional Ligands for the DHX15 RNA G-Quadruplex.ACS medicinal chemistry letters · 2024Article
- Inhibition of Leukotriene ACartilage · 2024Article
- Identification of Dhx15 as a Major Regulator of Liver Development, Regeneration, and Tumor Growth in Zebrafish and Mice.International journal of molecular sciences · 2024Article
- Androgen Receptor-Interacting Proteins in Prostate Cancer Development and Therapy Resistance.The American journal of pathology · 2024Review
- Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15.Nature communications · 2024Article
- Review
- A helicase-independent role of DHX15 promotes MYC stability and acute leukemia cell survival.iScience · 2024Article
- Emerging proteins involved in castration‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review).International journal of oncology · 2023Review
- RNA helicase DHX15 exemplifies a unique dependency in acute leukemia.Haematologica · 2023Article
- Functional roles of E3 ubiquitin ligases in prostate cancer.Journal of molecular medicine (Berlin, Germany) · 2022Review
- The RNA helicase DHX15 is a critical regulator of natural killer-cell homeostasis and functions.Cellular & molecular immunology · 2022Article
- The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.Journal of experimental & clinical cancer research : CR · 2022Article
- A model for DHX15 mediated disassembly of A-complex spliceosomes.RNA (New York, N.Y.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Y JingDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
M M NguyenDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
D WangDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
L E PascalDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
W GuoDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Y XuDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J AiDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
F-M DengDepartment of Pathology, NYU School of Medicine, New York, NY, USA.
K Z MasoodiDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
X YuDepartment of Geriatrics, Guangzhou General Hospital of Guangzhou Military Command; Guangdong Provincial Key Laboratory of Geriatric Infection and Organ Function Support; Guangzhou Key Laboratory of Geriatric Infection and Organ Function Support; Guangzhou, Guangdong, China.
J ZhangCenter for Translational Medicine, Guangxi Medical University, Nanning, Guangxi, China, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J B NelsonDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
S XiaDepartment of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Z WangDepartment of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center · USShanghai Jiao Tong University · CNGuangxi Medical University · CNNew York University · USSecond Xiangya Hospital of Central South University · CNShanghai First People's Hospital · CN
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MRoles of EAF2 in androgen action in the prostateR01CA186780 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, ZHOU · 2014 to 2018
$1.9MAR intracellular trafficking in prostate cancerR01CA108675 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, ZHOU · 2005 to 2009
$1.3MCellular mechanisms of androgen action and androgen-response gene EAF2 in prostate cancerR50CA211242 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PASCAL, LAURA ELLEN · 2016 to 2020
$575kNCI NIH HHS P30 CA047904NCI NIH HHS R01 CA108675NCI NIH HHS R01 CA186780NCI NIH HHS R50 CA211242
Abstract
Androgen receptor (AR) activation is critical for prostate cancer (PCa) development and progression, including castration resistance. The nuclear export signal of AR (NES
Indexed as
AnimalsCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMaleMiceMice, SCIDNeoplasm Recurrence, LocalNuclear Export SignalsNuclear ProteinsProstateProstate-Specific AntigenProstatic NeoplasmsAR protein, humanDHX15 protein, humanNuclear Export SignalsNuclear ProteinsProstate-Specific AntigenReceptors, AndrogenRNA HelicasesSeven in Absentia ProteinsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.